The Doris Duke Sickle Cell Disease/Advancing Cures award provides grants to advance curative approaches for sickle cell disease, including gene modification and drug therapies to restore hemoglobin function.

This award aims to support clinical research that will:

• Advance gene therapies for sickle cell disease into the clinic, including gene addition and genome editing.
• Build on globin regulatory mechanisms to restore red blood cell function.

In keeping with the wishes expressed in Doris Duke's will, experiments that use animals or primary tissues derived from animals will not be supported by this program.

Please see the Request for Applications document for information on how to apply. The deadline for submissions is May 31, 2019 at 3 p.m., ET.